ACADIA PHARMACEUTICALS INC

ACADNASDAQ

🏆 #1236 by market capEarnings Nov 4US Equity

$29.49▲ $0.08 (+0.26%)

Live

1h▲ 0.2%

24h▲ 0.3%

7d▲ 2.3%

14d▲ 11.9%

30d▲ 15.7%

1y▲ 15.9%

🏦Market Cap

$5.05B

Small Cap

📈Revenue Growth (YoY)

+11.9%

Healthy

📊Gross Margin

91.1%

High

💵FCF Margin

15.3%

Healthy

⚖️P/S Ratio

4.4x

Fair

Otter Score

Weak

Trading Snapshot

Day Range: $29.24 – $29.64
52-Week Range: $19.69 – $29.76
Volume: $2.52B
Avg Volume: $2.56B
Shares Outstanding: 171.2M
Next Earnings: Sep 1, 2026

Fundamentals Snapshot

Annual Revenue: $1.07B
Last Q Revenue: $308M
P/E Ratio: 13.1
P/S Ratio: 4.4x
EPS (TTM): $2.22
Dividend Yield: 0.00%

Why Investors Own ACAD

✓High-growth profile — revenue up +59.1% YoY with expanding US Equity exposure.
✓Healthy economics — 44% gross margin and 23% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$1.07B▲ +54.9% YoY

Gross Margin (TTM)

44.0%▲ +2.8% YoY

Operating Income (TTM)

$271M▲ +54.9% YoY

Free Cash Flow (TTM)

$246M▲ +54.9% YoY

About ACADIA PHARMACEUTICALS INC

ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.

🦦